TCTMD’s Top 10 Most Popular Stories for August 2021
Rare COVID-19 vaccine side effects and hot trials from the ESC 2021 Congress dominated our most popular stories this month.
The top stories on TCTMD this month were an even split between COVID-19 content and Hot Line news from the European Society of Cardiology (ESC) Congress 2021. All of TCTMD’s coverage from this year’s ESC meeting can be found on our conference page, along with video interviews led by our senior clinical editor, Mamas Mamas, BMBCh, DPhil.
We update our COVID-19 Dispatch with the top research and health policy news, as well as media highlights, three times per week.
The incidence is slightly higher than previously reported by the CDC, but investigators say the risks remain extremely small.
Most cases were short-lived and benign, but early evidence of LGE warrants following for potential myocardial scarring.
With statins, there is a shift toward denser, more-calcified plaque on CT, as well as less fibro-fatty and low-attenuation plaque.
It’s “a big day for patients living with HFpEF, a big day for heart failure clinicians,” observed Shelley Zieroth.
During the diagnostic angiogram, a physiologic assessment of all epicardial vessels was cost neutral but didn’t improve QoL.
This complication is “quite rare but potentially catastrophic,” Chip Lavie says. Early diagnosis and aggressive treatment are needed.
Empagliflozin in HFpEF, finerenone in diabetic kidney disease, a new LAA occluder, DOACs in TAVI, valve guidance, and more.
Investigators say the low-cost, easy-to-implement strategy could prevent up to 1 million major CVD events in China each year.
In an all-comers HBR group, 1-month DAPT was noninferior to 3 months or longer, at least with the bioresorbable stent used here.
A discussion of the ethics of using expired technology in parts of the world with no other options is long past due, some say.
Morton Kern, MD, asks: who’s playing tunes these days during cases and, if so, who gets to choose the playlist?